Concepedia

Michael Tanen

MT

22

Publications

4.1K

Citations

20

H-Index

1995

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Population Council

Rockefeller University

Duke University

Michael Tanen is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1995–2018

22

Publications

22

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization

Terry P. Combs, John A. Wagner, Joel P. Berger et al. · Endocrinology · 2002 · 566 citations

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 514 citations

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 498 citations

Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects

Joel P. Berger, Mark D. Leibowitz, Thomas W. Doebber et al. · Journal of Biological Chemistry · 1999 · 411 citations · Full text

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

, , +20

Rows per page

1–5 of 22